Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)
Recruiting now · Phase 1 · Has a placebo group
Conditions studied: Weight Management
In brief
The goal of this clinical study is to learn more about the study drug, GS-4571, and how safe it is in 3 groups, i) Healthy participants, ii) Healthy non-diabetic obese participants, and iii) Non-obese participants with Type 2 Diabetes Mellitus (T2DM). The primary objectives of this study are: * To characterize the pharmacokinetics (PK) of GS-4571 following single and multiple ascending oral doses of GS-4571. * To evaluate the effect of concomitant food intake and (if conducted) a representative acid-reducing agent (proton pump inhibitor (PPI), omeprazole) on the PK of GS-4571. * To evaluate the safety and tolerability of single and multiple ascending oral doses of GS-4571.
Key facts
- Study ID
- NCT06562907
- Run by
- Gilead Sciences
- People needed
- 134
- Starts
- 2024-08-28
- Expected to finish
- 2026-11-01
- Last updated by the study team
- 2026-06-22
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
Where it is running
- Qps-Mra, Llc. — Miami, Florida, United States (enrolling)
- ICON Early Phase Services, LLC — San Antonio, Texas, United States (enrolling)
- ICON — Salt Lake City, Utah, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.